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ABSTRACT
Introduction Immune-inflammatory response plays a key
role in the pathogenesis of atherosclerosis. IgG N-glycosylation
is reported to be associated with the 10-year atherosclerotic
cardiovascular disease risk score and subclinical
atherosclerosis. However, the relationship of IgG glycosylation
with actual clinical cardiovascular disease (CVD) events and
plaque phenotypes has rarely been investigated. Therefore,
this study aims to understand whether IgG glycosylation traits
are correlated with actual clinical CVD events and plaque
phenotypes.
Methods and analysis Designed to verify the efficacy of IgG
glycosylation as a risk for CVD events and screen potential
biomarkers of CVD to prevent atherosclerosis occurrence, this
longitudinal prospective cohort study will be conducted at the
First Affiliated Hospital of Shantou University Medical College,
China. In total, 2720 participants routinely examined by carotid
ultrasound will be divided into different groups according to
plaque phenotype characteristics. Ultra-performance liquid
chromatography will be performed to separate and detect
IgG N-glycans in serum collected at baseline and at the end
of the first, second and third years. The primary outcome is
the actual clinical CVD composite events, including non-fatal
myocardial infarction, death due to coronary heart disease,
and fatal or non-fatal stroke.
Ethics and dissemination The Clinical Ethics Committee
of the First Affiliated Hospital of Shantou University Medical
College approved this study (number: B-2021-127). Findings
of this study will be submitted for publication in peer-reviewed
journals.
Trial registration number ChiCTR2100048740.

INTRODUCTION
Background and scope
Atherosclerosis (AS) is a cardiovascular disease
(CVD) with high morbidity and mortality,
accounting for approximately 20% of all
deaths worldwide.1 Ischaemic heart disease
(IHD), ischaemic stroke and peripheral
vascular disease are the main serious outcomes
caused by AS.2 However, the pathogenesis of

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ This study is a longitudinal prospective cohort study

⇒

⇒

⇒

⇒

which will indicate change in IgG glycans in people
50–65 years of age.
The feasibility of this study is high as it does not
require treatment of participants with drugs or
surgery.
Due to the protective effects of oestrogen on atherosclerosis, this study will only involve postmenopausal women.
The cohort is derived from a single centre and represents only one ethnic group, Han Chinese, which
will lack ethnic diversity, and the results might not
be applicable to the general population.
Some biases, such as loss to follow-up and other uncontrollable factors, may exist, although this
study is designed to control the biases.

AS remains obscure. The main risk factors for
AS are family history, hypertension, smoking,
dyslipidaemia, diabetes and obesity. Other
factors such as metabolism disorders, platelet
activation, thrombosis, intimal damage, inflammatory response, oxidative stress and vascular
smooth muscle cell activation jointly promote
the occurrence and progression of AS.3–5 In
addition, whether some novel factors, such as
suboptimal health status and telomere length
in peripheral blood leucocytes, could increase
the risk of atherosclerotic cardiovascular disease
(ASCVD) is being investigated.6–8
Studies show that immune inflammation
exerts a significant role in atherogenesis.9
Animal experiments indicate that the initiation,
growth, differentiation and rupture of atherosclerotic plaques are influenced by the immune
system.10 A randomised controlled trial involving
10 061 patients demonstrated that targeted
immune anti-
inflammatory pathway therapy
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Objectives
We aim to understand whether IgG glycosylation traits are
correlated with plaque phenotypes and actual clinical CVD
composite events, including non-fatal myocardial infarction,
coronary heart disease death, and fatal or non-fatal stroke.

METHODS AND ANALYSIS
Design and setting
This study is an observational, single-
centre longitudinal
prospective cohort study to be conducted at the First Affiliated Hospital of Shantou University Medical College
(SUMC), Guangdong, China. The protocol applies the
checklists of the Standard Protocol Items: Recommendations
2

Participants (age 50-65 years old) examined by
carotid ultrasound in the Health Care Centre
Inclusion and exclusion criteria
Sign informed consent
Allocate according to carotid plaque type

CAS group

Control group

Subgroups according to
other plaque phenotypes

Collect clinical baseline data and serum, detect IgG
N-glycosylation by UPLC
Follow-up the CVD events and all-cause death in
the 1st, 2nd, and 3rd year
Data analysis

Figure 1 Participant distribution in the study. CAS, carotid
atherosclerosis; CVD, cardiovascular disease; UPLC,
ultrahigh-pressure liquid chromatography.

for Interventional Trials (SPIRIT) 2013 statement,30 a guideline for clinical trial design.
Participants
This study will be conducted in the Health Care Centre of
the First Affiliated Hospital of SUMC, where people over 50
years old are routinely recommended to be examined by
carotid ultrasonography for early diagnosis and detection
of carotid atherosclerosis (CAS) and early prevention of
CVD events. After the clinical study was registered on 15 July
2021, participants conventionally undergoing carotid artery
ultrasound examination will be recruited and divided into
different groups according to carotid plaque phenotypes
(figure 1). Potential eligible participants will be recorded
in real time by a sonographer. The research team consists
of physicians familiar with ultrasound examination and
academic staff skilled in clinical study design and statistical analysis. Furthermore, all investigators will obtain the
required research-related training before the start of the
study.
Inclusion criteria
Prospective participants will be carefully evaluated based
on the following inclusion criteria:
► Age between 50 and 65 years old.
► Had carotid ultrasound performed.
► Participants or their families provided informed
consent.
Exclusion criteria
Participants with any of the following will not be enrolled
in the study:
Tian C, et al. BMJ Open 2022;12:e058922. doi:10.1136/bmjopen-2021-058922
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significantly reduces CVD events, independent of lowering
lipid levels.11 Furthermore, germinal centre-derived IgG is a
determinant of plaque size and stability and effectively maintains the molecular properties of the aorta.12 Therefore, the
interaction of the adaptive immune system modulates the
progression of AS.
Glycosylation is the most abundant and diverse form of
post-
transcriptional modification in organisms, involved
in almost every physiological process, including immune
responses.13 14 Alterations in protein glycosylation are considered as the major event in the transition from health to
disease status.14 It has been demonstrated that IgG glycans
are associated with a variety of diseases, such as immune
system diseases,15 cancers,16–18 nervous system disease, 19
infectious diseases20 21 and haematological system diseases.22
Driven by specific enzymes, the complex carbohydrates
attached to immunoglobulins have specific regulatory
effects, which lead to differences in immune function.23 A
study revealed that glycosylation changes, especially for the
most abundant IgG in circulation, directly affect its inflammatory properties.24 For example, the anti-inflammatory and
proinflammatory activity of IgG are determined by sialylation
and agalactosylation, respectively.25 26 Furthermore, a cross-
sectional study indicated that deficiency in galactose and
sialic acid correlates with blood lipid levels.27 As the major
elements of life, the communication between glycans and
lipids even be proposed as a paracentral dogma.28 Therefore, considering the significant role of inflammation, especially immune inflammation in CVD development, different
IgG glycosylation traits may stratify the risk phenotypes for
CVD development.
Phenotypes of plaque include with or without plaque,
plaque stability, size, location and number. A cross-sectional
study based on two independent cohorts reported that the
glycosylation traits of IgG are associated with the 10-year
ASCVD risk score, subclinical AS and risk factors for CVD,
such as smoking, high-density lipoprotein cholesterol and
type 2 diabetes mellitus.29 However, it is unclear whether IgG
glycosylation correlates with actual clinical CVD events and
plaque phenotypes. Thus, we hypothesise that IgG N-glycan
profiling is an independent prognostic indicator of actual
clinical CVD composite events.
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►
►
►
►

Participants with complications such as IHD, stroke,
infection, immune system disease, nervous system
disease, haematological system disease and cancer.
History of lipid-lowering therapy.
History of anticoagulant therapy or antiplatelet
therapy or vasodilator therapy.
History of intravenous immunoglobulin or blood
transfusion within 1 month.
Irregular follow-up.

Withdrawal
Participants may withdraw their participation from
the study for any reason.
► Other circumstances: based on the investigator’s
judgement, the participant no longer meets the study
criteria for any reason.
►

Blinding
Participants, sonographers, data gatherers and data
analysts are not blinded to group assignments, whereas
specimen examiners and follow-up staffers are blinded.
Data collection and management
Information from the enrolled participants, including
smoking history, diabetes status and antihypertensive
medication, along with low-density lipoprotein (LDL),
high-density lipoprotein, triacylglycerol and total cholesterol levels, will be assembled. In addition, a sonographer will inspect the characteristics of carotid plaque,
including plaque size, number, site, blood flow, echo,
shape and stability. All data will be kept through EpiData
(V.3.1; Denmark), an electronic data capture applied for
data entry. Furthermore, 1 mL serum will be collected
from each participant at different times (enrolment, first
year, second year and third year) after being centrifuged
at 604 g for 10 min at 277.15 K. Serum will be stored in
the freezer at −80℃ for biochemistry and glycan analysis.
Follow-up
The survival status (surviving/deceased) and actual clinical CVD composite events of the participants, including
CVD death, myocardial infarction and stroke, will be
followed up at the end of the first, second and third years
by two trained investigators through telephone, outpatient visit and physical examination. Furthermore, serum
samples will be collected every year and used for detection of IgG glycans (figure 2).
Sample size
It has been reported that the incidence of CVD events
is about 6%.31 According to Liu et al,32 among 24 IgG
glycan peaks (GPs), GP6 is significantly different between
people with and without ischaemic stroke (5.00 (4.26,
5.85) vs 4.48 (3.93, 4.35), p=0.028) and therefore can
be used to roughly estimate the sample size. Converting
median and quartile to mean and SD is necessary for the
sample size.33–35 Taking the incidence of CVD events and
this conversion into consideration, 2267 participants will
be needed, based on an α of 0.05 on a two-sided test and
Tian C, et al. BMJ Open 2022;12:e058922. doi:10.1136/bmjopen-2021-058922

90% power, to obtain a statistical difference. An additional one-fifth is required for the total sample size when
considering cases of lost to follow-up and refusal to visit.
Finally, a total of 2720 participants are required for the
study. The sample size was calculated using PASS software
(V.11; NCSS, America).
Carotid ultrasound
Colour Doppler ultrasonography (Siemens Acuson
X150) will be used to scan the carotid artery. Participants
will be held on a supine position with the head turned to
the opposite side and the probe moved from the root of
the neck to the head. The common carotid artery, bifurcation, internal carotid artery and external carotid artery
are scanned. Based on the diameter, plaque morphology
and echo characteristics, the plaques are classified into
three types (soft plaques: uniform or uneven images,
irregular form, weak and low echo; hard plaques: strong
echo, uneven thickening of the tube wall with enhanced
echo and sound shadow behind; mixed plaques: uneven
echo, unequal intensity, irregular shape, large image
range). Hard plaques are defined as stable plaques, while
soft and mixed plaques are regarded as unstable plaques.
Ultrahigh-pressure liquid chromatography
IgG glycosylation will be detected by ultrahigh-pressure
liquid chromatography (UPLC) (LC-30AD, Shimadzu).
First, IgG will be isolated with a protein G extraction
plate. After being dried and exposed to peptide-
N-
glycosidase F, N-
glycan will be released and labelled
with 2-
aminobenzamide fluorescent dye. Furthermore,
the free markers and reducing agents will be removed
by hydrophilic chromatography-
solid phase extraction.
Subsequently, fluorescently-
labelled N-
glycans will be
separated by hydrophilic chromatography on UPLC.36
Finally, an automatic processing method with a traditional integration algorithm is used for data processing.
Each chromatogram is manually corrected to ensure the
same integration interval for all samples.
Outcome measurements
The primary outcome of this study is the composite events
of CVD. The secondary outcome is the 3-year mortality by
counting all-cause death.
Statistical and analytical plans
Categorical variables will be expressed by frequency
(percentage) and univariate analysis will be performed
using the χ2 test. Data of normal distribution are shown as
mean±SD. The t-test and analysis of variance are used for
comparison of two groups and multiple groups, respectively. Non-
normally distributed data are represented
by median (P25, P75). Univariate analysis is performed
by non-parametric testing. Interpolation is carried out
according to the type of data loss. If the lost data are
of numerical type, the average value is used to fill it.
However, if the lost data are non-numerical, the value
with the highest occurrence frequency in this index is
filled in. Logistic regression will be applied to analyse the
3
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Enrollment Distribution
Timepoint
Enrollment
Prescreening
Eligibility screen
Informed consent
Distribution
Control group
CAS group
Assessments
Gender
Age
Smoking
Diabetes
Hypotensor
LDL
HDL
TC
TG
Carotid ultrasound
Size
Number
Situation
Blood flow
Echo
Shape
Stability
Serum
UPLC
Ig G glycosylation
Outcome
Non-fatal MI
CHD death
Stroke
All-cause death
Analysis

D0

D1

UPLC

Follow-up

W1

Y1

Y2

Y3

X

X

X

X

X
X
X
X

X
X
X
X

X
X
X
X

Close-out

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

X

Figure 2 Schedule of enrolment, distribution and assessment in the study. CAS, carotid atherosclerosis; CHD, coronary heart
disease; D, day; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; TC, total cholesterol; TG,
triacylglycerol; UPLC, ultrahigh-pressure liquid chromatography; W, week; Y, year.

association between IgG N-
glycosylation characteristics
and CVD events. Subsequently, a glycan risk score will
be created to evaluate the associative effects of all glycan
traits screened. A p value <0.05 indicates statistical significance. SPSS software (V.26.0) will be used for statistical
analysis.

researchers, independent of the sponsor and conflict
of interest, make up the DMC, which will evaluate
the data after a quarter, a half and three-quarters of
the participants voluntarily enrol in this study. The
six researchers will be involved in the entire research
progress.

Monitoring
This study will be conducted critically according to the
approved proposal. The data and safety monitoring
committee (DMC) of our hospital will undertake the
responsibility of data review and interpretation, which
is beneficial to the security and privacy of the participants and to the validity and integrity of the data. Six

Auditing
Based on state regulations, the audit work will be
conducted during the entire study process to trace
the changes and guarantee the quality of research
data. Representatives from the ethics committee will
shoulder the obligation to inform the related parties of
all proposal revisions.
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Open access

Amendment
Any modifications to the proposal will be submitted to the
Clinical Ethics Committee and DMC for consent.
ETHICS AND DISSEMINATION
Ethics approval
The study protocol was approved by the Clinical Ethics
Committee of the First Affiliated Hospital of SUMC on 13
July 2021 (number: B-2021-127).
Informed consent
Before enrolment, the investigator will introduce the main
purpose and content of the study to the participants. In addition, participants will be informed of the possible risks and
benefits of the research to ensure that their participation
is completely voluntary. After participants have signed the
informed consent, all study-related data, including personal
information, will be kept confidential. This study will be
carried out in accordance with the principles of the Declaration of Helsinki.
Dissemination
All data and findings of this study will be disseminated at
scientific conferences or submitted for publication in peer-
reviewed journals.
DISCUSSION
AS can lead to acute myocardial infarction, cerebral infarction and other serious consequences, which seriously affect
quality of life and bring a huge economic burden to patients
and society. It has been reported that at the beginning of
2010 the total hospitalisation cost of patients with CVD was
over ¥40 billion, which contributes to more than 1.60% of
the national health expenditure.37 ASCVD has become a
major public health problem worldwide, making the prevention and treatment of CVD urgent.
A large amount of evidence shows that the pathogenesis of
AS is mainly related to the adaptive immune-inflammatory
response. AS contains IgG antibodies against LDL, oxidised
LDL and apolipoprotein B (ApoB).38 Some studies suggest
that IgG antibody titre is positively correlated with AS,
whether in mice or humans,39 and that anti-ApoB IgG antibody can aggravate AS.40 In vitro experiments demonstrate
that IgG and very low-density lipoprotein are responsible
for forming arterial lesions.41 As an immunoinflammatory
biomarker, IgG glycosylation is effective in differentiating
patients with dyslipidaemia from the healthy, displaying an
area under the curve of approximately 0.7 in a cross-sectional
study of Chinese Han.27 Removal of glycans contributes to
the disappearance of the anti-inflammatory properties of
IgG,42 while the enrichment of sialic acid is responsible for
a 10-
fold increase in the anti-
inflammatory properties of
Tian C, et al. BMJ Open 2022;12:e058922. doi:10.1136/bmjopen-2021-058922

IgG.43 Therefore, control of the adaptive immune response
through immune regulatory strategies or vaccination is a
potential therapeutic direction for AS.
Glycoprotein acetylation (GlycA), a more reliable
compound biological marker of systemic inflammation, has
potential value in predicting CVD outcomes and reflecting
inflammation.29 44–47 However, GlycA is a glycan signal of
a single measure based on nuclear magnetic resonance.
Therefore, the association between IgG N-glycosylation with
richer glycoprotein traits and CVD composite events will
be assessed in this study. If the results of this study show a
significant correlation between IgG glycosylated traits and
actual clinical CVD composite events, it will provide further
evidence on the role of glycosylation modification and
immune-inflammatory response in AS, as well as a potential biomarker better than GlycA in predicting CVD events
in the clinic. In addition, clarifying the correlation between
IgG and AS and revealing the mechanism of atherogenesis
are essential to providing new directions for treatment and
prevention of CVD. Our study will provide important scientific significance and socioeconomic value for improving
the quality of life and decreasing the mortality rate and the
socioeconomic burden of patients with CVD.
However, some limitations to this study exist. First, the
participants are recruited at a single centre and represent
only one ethnic group, Han Chinese, in the Chaoshan
area of Guangdong Province and thus lack ethnic diversity.
Further, a multicentre cohort study is required for application of results to the general population. Second, follow-up
bias is inevitable in this prospective cohort study due to the
existence of subjects who may migrate, leave or withdraw
from this cohort, although the authors will try their best to
control it.

TRIAL STATUS
Participant recruitment began on 15 July 2021 and will be
finished by 31 December 2021.
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Harms
This non-intervention study is remarkably safe. Participants
will get no exposure to any drug-related or surgery-related
therapies.

Open access
Patient and public involvement Patients and/or the public were not involved in
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits
others to copy, redistribute, remix, transform and build upon this work for any
purpose, provided the original work is properly cited, a link to the licence is given,
and indication of whether changes were made. See: https://creativecommons.org/
licenses/by/4.0/.
ORCID iD
Cuihong Tian http://orcid.org/0000-0002-3688-072X

REFERENCES

1 Wang Y, Xie Y, Zhang A, et al. Exosomes: an emerging factor in
atherosclerosis. Biomed Pharmacother 2019;115:108951.
2 Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis
Primers 2019;5:56.
3 Gupta M, Blumenthal C, Chatterjee S, et al. Novel emerging
therapies in atherosclerosis targeting lipid metabolism. Expert Opin
Investig Drugs 2020;29:611–22.
4 Kattoor AJ, Pothineni NVK, Palagiri D, et al. Oxidative stress in
atherosclerosis. Curr Atheroscler Rep 2017;19:42.
5 Ji Y, Bai C. Research progress of hypertriglyceridemia and coronary
heart disease. Heart Mind 2018;2:40–44.
6 Wang Y, Ge S, Yan Y, et al. China suboptimal health cohort study:
rationale, design and baseline characteristics. J Transl Med
2016;14:291.
7 Cao W, Zheng D, Zhang J, et al. Association between telomere
length in peripheral blood leukocytes and risk of ischemic stroke
in a Han Chinese population: a linear and non-linear Mendelian
randomization analysis. J Transl Med 2020;18:385.
8 Liu M. Spotlight on the relationship between heart disease and
mental stress. Heart Mind 2021;5:1–3.
9 Sage AP, Mallat Z. Readapting the adaptive immune response
- therapeutic strategies for atherosclerosis. Br J Pharmacol
2017;174:3926–39.
10 Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms
implicated in atherosclerosis: from mice to humans. Immunity
2013;38:1092–104.
11 Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy
with canakinumab for atherosclerotic disease. N Engl J Med
2017;377:1119–31.
12 Centa M, Jin H, Hofste L, et al. Germinal center-derived antibodies
promote atherosclerosis plaque size and stability. Circulation
2019;139:2466–82.
13 Molinari M. N-Glycan structure dictates extension of protein folding
or onset of disposal. Nat Chem Biol 2007;3:313–20.
14 Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health
and disease. Cell 2006;126:855–67.
15 Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid
arthritis and primary osteoarthritis with changes in the glycosylation
pattern of total serum IgG. Nature 1985;316:452–7.
16 Yi C-H, Weng H-L, Zhou F-G, et al. Elevated core-fucosylated IgG is
a new marker for hepatitis B virus-related hepatocellular carcinoma.
Oncoimmunology 2015;4:e1011503.
17 Bones J, Byrne JC, O'Donoghue N, et al. Glycomic and
glycoproteomic analysis of serum from patients with stomach
cancer reveals potential markers arising from host defense response
mechanisms. J Proteome Res 2011;10:1246–65.
18 Qian Y, Wang Y, Zhang X, et al. Quantitative analysis of serum IgG
galactosylation assists differential diagnosis of ovarian cancer.
J Proteome Res 2013;12:4046–55.
19 Costa J, Streich L, Pinto S, et al. Exploring cerebrospinal fluid IgG N-
glycosylation as potential biomarker for amyotrophic lateral sclerosis.
Mol Neurobiol 2019;56:5729–39.
20 Giron LB, Azzoni L, Yin X, et al. Hepatitis C virus modulates IgG
glycosylation in HIV co-infected antiretroviral therapy suppressed
individuals. AIDS 2020;34:1461–6.
21 Šimurina M, de Haan N, Vučković F, et al. Glycosylation of
immunoglobulin G associates with clinical features of inflammatory
bowel diseases. Gastroenterology 2018;154:1320–33.

6

22 Lauc G, Huffman JE, Pučić M, et al. Loci associated with N-
glycosylation of human immunoglobulin G show pleiotropy with
autoimmune diseases and haematological cancers. PLoS Genet
2013;9:e1003225.
23 Maverakis E, Kim K, Shimoda M, et al. Glycans in the immune
system and the altered glycan theory of autoimmunity: a critical
review. J Autoimmun 2015;57:1–13.
24 Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and
inflammation. Nat Rev Immunol 2010;10:301–16.
25 Washburn N, Schwab I, Ortiz D, et al. Controlled tetra-Fc
sialylation of IVIg results in a drug candidate with consistent
enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A
2015;112:E1297–306.
26 Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG
antibodies depend on cellular Fc receptors for in vivo activity. Proc
Natl Acad Sci U S A 2007;104:8433–7.
27 Liu D, Chu X, Wang H, et al. The changes of immunoglobulin G
N-glycosylation in blood lipids and dyslipidaemia. J Transl Med
2018;16:235.
28 Wang W. Glycomedicine: the current state of the art. Engineering.
29 Menni C, Gudelj I, Macdonald-Dunlop E, et al. Glycosylation
profile of immunoglobulin G is cross-sectionally associated with
cardiovascular disease risk score and subclinical atherosclerosis in
two independent cohorts. Circ Res 2018;122:1555–64.
30 Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement:
defining standard protocol items for clinical trials. Ann Intern Med
2013;158:200–7.
31 Kotruchin P, Hoshide S, Kario K. Carotid atherosclerosis and
the association between nocturnal blood pressure dipping and
cardiovascular events. J Clin Hypertens 2018;20:450–5.
32 Liu D, Zhao Z, Wang A, et al. Ischemic stroke is associated with the
pro-inflammatory potential of N-glycosylated immunoglobulin G.
J Neuroinflammation 2018;15:123.
33 Shi J, Luo D, Weng H, et al. Optimally estimating the sample
standard deviation from the five-number summary. Res Synth
Methods 2020;11:641–54.
34 Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean
from the sample size, median, mid-range, and/or mid-quartile range.
Stat Methods Med Res 2018;27:1785–805.
35 Wan X, Wang W, Liu J, et al. Estimating the sample mean and
standard deviation from the sample size, median, range and/or
interquartile range. BMC Med Res Methodol 2014;14:135.
36 Liu D, Xu X, Li Y, et al. Immunoglobulin G N-glycan analysis by
ultra-performance liquid chromatography. J Vis Exp 2020;155:60104.
doi:10.3791/60104
37 Hu SS, Kong LZ, Gao RL, et al. Outline of the report on
cardiovascular disease in China, 2010. Biomed Environ Sci
2012;25:251–6.
38 Kimura T, Tse K, Sette A, et al. Vaccination to modulate
atherosclerosis. Autoimmunity 2015;48:152–60.
39 Björkbacka H, Alm R, Persson M, et al. Low levels of apolipoprotein
B-100 autoantibodies are associated with increased risk of coronary
events. Arterioscler Thromb Vasc Biol 2016;36:765–71.
40 Tay C, Liu Y-H, Kanellakis P, et al. Follicular B cells promote
atherosclerosis via T cell-mediated differentiation into plasma cells
and secreting pathogenic immunoglobulin G. Arterioscler Thromb
Vasc Biol 2018;38:e71–84.
41 Sarphie TG. Interactions of IgG and beta-VLDL with aortic valve
endothelium from hypercholesterolemic rabbits. Atherosclerosis
1987;68:199–212.
42 Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity
of immunoglobulin G resulting from Fc sialylation. Science
2006;313:670–3.
43 Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy:
how does IgG modulate the immune system? Nat Rev Immunol
2013;13:176–89.
44 Duprez DA, Otvos J, Sanchez OA, et al. Comparison of the predictive
value of GlycA and other biomarkers of inflammation for total death,
incident cardiovascular events, noncardiovascular and noncancer
inflammatory-related events, and total cancer events. Clin Chem
2016;62:1020–31.
45 Akinkuolie AO, Buring JE, Ridker PM, et al. A novel protein glycan
biomarker and future cardiovascular disease events. J Am Heart
Assoc 2014;3:e001221.
46 Lawler PR, Akinkuolie AO, Chandler PD, et al. Circulating N-linked
glycoprotein acetyls and longitudinal mortality risk. Circ Res
2016;118:1106–15.
47 McGarrah RW, Kelly JP, Craig DM, et al. A novel protein
glycan-derived inflammation biomarker independently predicts
cardiovascular disease and modifies the association of HDL
subclasses with mortality. Clin Chem 2017;63:288–96.

Tian C, et al. BMJ Open 2022;12:e058922. doi:10.1136/bmjopen-2021-058922

BMJ Open: first published as 10.1136/bmjopen-2021-058922 on 22 July 2022. Downloaded from http://bmjopen.bmj.com/ on September 18, 2022 by guest. Protected by copyright.

Competing interests None declared.

